FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402910> ?p ?o ?g. }

• W4308402910 abstract "<h3>Background</h3> CD40 agonist mAbs can enhance the efficacy of checkpoint blockade in preclinical models and can functionally revive PD-1^hi exhausted T cells. This Phase 1 study examined safety, clinical activity, and pharmacodynamics of CDX-1140 as monotherapy or in combination with other agents (NCT03329950). We now report the completed results from Part 3 of the study, combination with anti-PD-1 mAb pembrolizumab. <h3>Methods</h3> Patients with advanced solid tumors and documented disease progression on a single prior anti-PD-1/L1 based regimen were enrolled. In dose-escalation (DE) cohorts, CDX-1140 was administered at 0.72 mg/kg and 1.5 mg/kg. Expansion cohorts (EX) in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of head and neck (SCCHN) evaluated CDX-1140 1.5 mg/kg. Treatment was q3w co-administered with pembrolizumab 200 mg in both DE and EX. <h3>Results</h3> 10 patients were treated in DE (renal cell carcinoma n=2, SSCHN n=2, n=1 for NSCLC, endometrial cancer, MSI^hi-CRC, ocular melanoma, esophageal adenocarcinoma, MSI^hi-cholangiocarcinoma) and 15 patients treated in EX; NSCLC (n=9) and SCCHN (n=6). The median number of prior regimens was 3. Treatment was generally well tolerated, with most treatment-related AEs (TRAE) being grade 1 or 2. The most frequent TRAE at the CDX-1140 1.5 mg/kg dose level (n=21) were arthralgia (62%), fatigue (62%), nausea (48%), diarrhea (48%), vomiting (43%), myalgia (43%), fever (38%), chills (38%), AST increase (38%), bilirubin increase (24%), ALT increase (19%), and cytokine release syndrome (CRS) (19%). Across Part 3, there was 1 complete response (CR) in a patient with oropharyngeal cancer (HPV⁺ and PD-L1 status unknown); 9 additional patients had stable disease (SD), including 4 with SCCHN and 4 with NSCLC. The patient achieving CR received 4 prior regimens (including chemotherapy, pembrolizumab, and cetuximab), discontinued study therapy after 2 doses due to arthralgia (grade 3) and CRS (grade 2), and initially demonstrated a partial response that evolved into CR, with the response ongoing at 12+ months without further anti-tumor treatment. Of the 4 SCCHN with SD, 2 had target lesions shrinkage (-15% and -18%) and 2 had no change. One NSCLC patient has SD for 10+ months with a nadir in target lesions of -15%. Part 3 biomarker data will be presented. <h3>Conclusions</h3> CDX-1140 in combination with pembrolizumab had an acceptable safety profile. Evidence of clinical benefit was most evident in patients with SCCHN, all of whom had progressive disease on prior anti-PD-1/L1 based therapies. Further studies are warranted. <h3>Trial Registration </h3> NCT03329950 <h3>Ethics Approval</h3> The study was reviewed and approved by the following institutional review boards: Providence Health & Services Institutional Review Board for Earle A. Chiles Research Institute/Providence Cancer Institute; approval number/ID: PHS IRB #2017000532 WCG-IRB for Gabrail Cancer Center, Georgia Cancer Specialists, HonorHealth Research Institute, and Nebraska Cancer Specialists; approval number/ID: 20172645 Rhode Island Hospital IkRB#1 for Legorreta Cancer Center at Brown University/Rhode Island Hospital/Lifespan Cancer Center; approval number/ID: LS-P-Camp Office of Regulatory Affairs of the University of Pennsylvania for Hospital of the University of Pennsylvania; approval number/ID: UPCC 18917 Memorial Sloan Kettering Cancer Center Institutional Review Board/Privacy Board; approval number/ID: 18-225 Participants gave informed consent before taking part in the study." @default.
• W4308402910 created "2022-11-11" @default.
• W4308402910 creator A5001193982 @default.
• W4308402910 creator A5005462156 @default.
• W4308402910 creator A5014236598 @default.
• W4308402910 creator A5020755903 @default.
• W4308402910 creator A5035148529 @default.
• W4308402910 creator A5042029338 @default.
• W4308402910 creator A5049860213 @default.
• W4308402910 creator A5055698553 @default.
• W4308402910 creator A5062558399 @default.
• W4308402910 creator A5066367673 @default.
• W4308402910 creator A5069690249 @default.
• W4308402910 creator A5069923958 @default.
• W4308402910 creator A5075823692 @default.
• W4308402910 creator A5079389968 @default.
• W4308402910 creator A5082159021 @default.
• W4308402910 creator A5082283453 @default.
• W4308402910 date "2022-11-01" @default.
• W4308402910 modified "2023-09-26" @default.
• W4308402910 title "596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab" @default.
• W4308402910 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0596" @default.
• W4308402910 hasPublicationYear "2022" @default.
• W4308402910 type Work @default.
• W4308402910 citedByCount "0" @default.
• W4308402910 crossrefType "proceedings-article" @default.
• W4308402910 hasAuthorship W4308402910A5001193982 @default.
• W4308402910 hasAuthorship W4308402910A5005462156 @default.
• W4308402910 hasAuthorship W4308402910A5014236598 @default.
• W4308402910 hasAuthorship W4308402910A5020755903 @default.
• W4308402910 hasAuthorship W4308402910A5035148529 @default.
• W4308402910 hasAuthorship W4308402910A5042029338 @default.
• W4308402910 hasAuthorship W4308402910A5049860213 @default.
• W4308402910 hasAuthorship W4308402910A5055698553 @default.
• W4308402910 hasAuthorship W4308402910A5062558399 @default.
• W4308402910 hasAuthorship W4308402910A5066367673 @default.
• W4308402910 hasAuthorship W4308402910A5069690249 @default.
• W4308402910 hasAuthorship W4308402910A5069923958 @default.
• W4308402910 hasAuthorship W4308402910A5075823692 @default.
• W4308402910 hasAuthorship W4308402910A5079389968 @default.
• W4308402910 hasAuthorship W4308402910A5082159021 @default.
• W4308402910 hasAuthorship W4308402910A5082283453 @default.
• W4308402910 hasBestOaLocation W43084029101 @default.
• W4308402910 hasConcept C121608353 @default.
• W4308402910 hasConcept C126322002 @default.
• W4308402910 hasConcept C143998085 @default.
• W4308402910 hasConcept C197934379 @default.
• W4308402910 hasConcept C2777701055 @default.
• W4308402910 hasConcept C2778375690 @default.
• W4308402910 hasConcept C2780057760 @default.
• W4308402910 hasConcept C2780580376 @default.
• W4308402910 hasConcept C2781413609 @default.
• W4308402910 hasConcept C71924100 @default.
• W4308402910 hasConcept C90924648 @default.
• W4308402910 hasConceptScore W4308402910C121608353 @default.
• W4308402910 hasConceptScore W4308402910C126322002 @default.
• W4308402910 hasConceptScore W4308402910C143998085 @default.
• W4308402910 hasConceptScore W4308402910C197934379 @default.
• W4308402910 hasConceptScore W4308402910C2777701055 @default.
• W4308402910 hasConceptScore W4308402910C2778375690 @default.
• W4308402910 hasConceptScore W4308402910C2780057760 @default.
• W4308402910 hasConceptScore W4308402910C2780580376 @default.
• W4308402910 hasConceptScore W4308402910C2781413609 @default.
• W4308402910 hasConceptScore W4308402910C71924100 @default.
• W4308402910 hasConceptScore W4308402910C90924648 @default.
• W4308402910 hasLocation W43084029101 @default.
• W4308402910 hasOpenAccess W4308402910 @default.
• W4308402910 hasPrimaryLocation W43084029101 @default.
• W4308402910 hasRelatedWork W2007986200 @default.
• W4308402910 hasRelatedWork W2087848499 @default.
• W4308402910 hasRelatedWork W2359850731 @default.
• W4308402910 hasRelatedWork W3103265772 @default.
• W4308402910 hasRelatedWork W3165165741 @default.
• W4308402910 hasRelatedWork W4212796756 @default.
• W4308402910 hasRelatedWork W4213121772 @default.
• W4308402910 hasRelatedWork W4224862170 @default.
• W4308402910 hasRelatedWork W4285098856 @default.
• W4308402910 hasRelatedWork W4312129293 @default.
• W4308402910 isParatext "false" @default.
• W4308402910 isRetracted "false" @default.
• W4308402910 workType "article" @default.